Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) vs Merck & Co., Inc. (MRK) Price & Performance

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)Trade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Haleon plc American Depositary Shares (Each representing two Ordinary Shares) vs Merck & Co., Inc. — how do they compare? Haleon plc American Depositary Shares (Each representing two Ordinary Shares) trades at $9.28 (market cap $40.01B), while Merck & Co., Inc. trades at $141.98 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 8.8× Haleon plc American Depositary Shares (Each representing two Ordinary Shares)'s market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Haleon plc American Depositary Shares (Each representing two Ordinary Shares) for 0 Days and Merck & Co., Inc. for 98 Days on average.

HLNMRK
Market Cap
$40.01B$351.28B
Volume
19,985,9357,969,665
Sector
HealthHealth
52-Week High
$11.27$156.43
52-Week Low
$8.70$82.49
Typical Hold Time
0 Days98 Days
Enterprise Value
$49.79B$398.04B
Dividend Yield
2.14%2.39%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.

The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HLN
100% Buy0% Sell
Avg holding period · 0 Days
MRK
18% Buy82% Sell
Avg holding period · 98 Days

Top news

Latest headlines on both assets

About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon is a consumer healthcare company offering over-the-counter medicines, oral health products, vitamins, and wellness brands.

Read more on HLN →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK →